Alzheimer's Disease (AD) Clinical Trial
Official title:
Effects of Auditory Brain Stimulation by "Pink Noise" on Memory Capacities in Alzheimer's Disease: Proof of Concept Study
Alzheimer's disease (AD) is a neurodegenerative disorder affecting almost 6% of the world's population over the age of 65. This disease, in its most typical sporadic form, is characterized by an episodic memory impairment linked to a deficit in consolidation. Many studies indicate that sleep promotes this consolidation stage during the deep slow sleep stage by facilitating the transfer of information between the hippocampus and the neocortex. A method of acoustic brain stimulation at night by pink noises has been recently developed and has shown its effectiveness in strengthening memory consolidation in healthy volunteers. Actually, there is no study observing the effect of this new stimulation method on populations with neurodegenerative pathologies, in particular in AD for which this technique could potentially become a therapeutic option. The hypothesis is that of a strengthening of the memory consolidation capacities in subjects with AD as has been shown in healthy subjects.
Alzheimer's disease (AD) is a neurodegenerative disorder affecting almost 6% of the world's population over the age of 65. This disease, in its most typical sporadic form, is characterized by an episodic memory impairment linked to a deficit in consolidation. Many studies indicate that sleep promotes this consolidation stage during the deep slow sleep stage by facilitating the transfer of information between the hippocampus and the neocortex. A method of acoustic brain stimulation at night by pink noises has been recently developed and has shown its effectiveness in strengthening memory consolidation in healthy volunteers. Actually, there is no study observing the effect of this new stimulation method on populations with neurodegenerative pathologies, in particular in AD for which this technique could potentially become a therapeutic option. The hypothesis is that of a strengthening of the memory consolidation capacities in subjects with AD as has been shown in healthy subjects. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02503501 -
Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease
|
Phase 2 | |
| Recruiting |
NCT02854033 -
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
|
||
| Completed |
NCT02681172 -
Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD
|
Phase 4 | |
| Completed |
NCT02593318 -
Trial of Oxaloacetate in Alzheimer's Disease (TOAD)
|
Phase 1 | |
| Completed |
NCT02264899 -
MEMENTO-VAScular COmponents of Dementia
|
N/A | |
| Completed |
NCT02531360 -
Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies
|
Phase 0 | |
| Not yet recruiting |
NCT05592678 -
δ in Dementia Clinical Trials
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT05558709 -
Social-cognitive Functioning: Validation of a New Neuropsychological Test
|
N/A | |
| Recruiting |
NCT05059158 -
Amyloid-β Clearance Mechanisms in Alzheimer's Disease
|
||
| Recruiting |
NCT02832921 -
Cognitive-motor Intervention Using Virtual Reality for Middle-aged Individuals at High Dementia Risk
|
N/A | |
| Completed |
NCT02370524 -
Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease
|
Phase 1 | |
| Completed |
NCT01780519 -
The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms
|
Phase 1 | |
| Completed |
NCT02103894 -
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
|
Phase 1 | |
| Completed |
NCT03802162 -
A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-355
|
Phase 1 | |
| Completed |
NCT01231971 -
Alzheimer's Disease Neuroimaging Initiative 2
|
||
| Recruiting |
NCT05291234 -
A Study to Assess Safety of ABBV-916 and How Intravenous ABBV-916 Moves Through Body and Affects Brain Amyloid Plaque Clearance in Adult Participants (Aged 50-90 Years) With Early Alzheimer's Disease
|
Phase 2 | |
| Active, not recruiting |
NCT05771428 -
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
|
Phase 2 | |
| Recruiting |
NCT06114745 -
A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
|
Phase 1 |